This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
In the article the authors examine the April 2 Executive Order signed by President Trump highlighting US trading partners’ nontariff barriers, such as...
Competitive rare diseases: Setting the scene In the first installment of a new series on competitive categories in rare diseases, CRA Life Sciences’s Bhavesh...
CRA is a proud sponsor of the epicenter of the specialty pharmacy industry event. Becky Davis presents the session titled “GLP-1s: Riding the Wave of...
Hannah Armstrong moderates the session titled “Addressing Challenges with Access to Fertility Treatment and Preservation in APAC: Policy Recommendations for...
